Changes in urodynamic parameters after tolterodine treatment for female overactive bladder syndrome with or without...

Area of Science:

• Urology
• Pharmacology

Background:

• Overactive bladder syndrome (OAS) is a common condition affecting women.
• Tolterodine is a commonly prescribed medication for OAS.
• The impact of tolterodine on urodynamic parameters, particularly in patients with co-existing voiding dysfunction, requires further investigation.

Purpose of the Study:

• To evaluate the effects of tolterodine on urodynamic parameters in women with overactive bladder syndrome.
• To specifically assess if voiding dysfunction influences the treatment response to tolterodine.

Main Methods:

• A prospective study involving 44 female patients with overactive bladder syndrome.
• Six months of treatment with tolterodine.
• Urodynamic studies were conducted pre-treatment and post-treatment.

Main Results:

• Tolterodine treatment led to a significant increase in bladder capacity (P < 0.001) and post-void residual urine (P = 0.009).
• A significant decrease was observed in functional urethral length (P = 0.049) and pad weight test results (P = 0.03).
• Patients with voiding dysfunction showed less significant changes in parameters like detrusor pressure at maximal urine flow and urethral pressures compared to those without voiding dysfunction.

Conclusions:

• Tolterodine effectively increases bladder capacity and reduces urine leakage in women with overactive bladder syndrome.
• The efficacy of tolterodine on specific urodynamic parameters may be diminished in patients who also present with voiding dysfunction.